Concepts (84)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Dasatinib | 6 | 2018 | 40 | 0.590 |
Why?
|
| Leukemia, Myeloid, Chronic-Phase | 4 | 2018 | 11 | 0.550 |
Why?
|
| Protein Kinase Inhibitors | 5 | 2018 | 530 | 0.410 |
Why?
|
| Imatinib Mesylate | 6 | 2018 | 44 | 0.400 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 4 | 2016 | 98 | 0.370 |
Why?
|
| Antineoplastic Agents | 5 | 2016 | 1664 | 0.270 |
Why?
|
| Oropharyngeal Neoplasms | 2 | 2018 | 163 | 0.250 |
Why?
|
| Antibodies, Bispecific | 1 | 2025 | 34 | 0.230 |
Why?
|
| Thiazoles | 2 | 2014 | 97 | 0.210 |
Why?
|
| Sentinel Lymph Node | 1 | 2023 | 7 | 0.210 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2025 | 141 | 0.210 |
Why?
|
| Febrile Neutropenia | 1 | 2022 | 13 | 0.210 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2018 | 662 | 0.200 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2022 | 138 | 0.190 |
Why?
|
| Pyrimidines | 2 | 2014 | 372 | 0.180 |
Why?
|
| Thrombocytopenia | 1 | 2022 | 227 | 0.180 |
Why?
|
| Disease-Free Survival | 6 | 2018 | 868 | 0.160 |
Why?
|
| Chymases | 1 | 2018 | 6 | 0.150 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2025 | 825 | 0.150 |
Why?
|
| Drug Substitution | 1 | 2018 | 19 | 0.150 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2022 | 538 | 0.140 |
Why?
|
| Benzamides | 2 | 2014 | 106 | 0.130 |
Why?
|
| Leukemia, Myeloid, Accelerated Phase | 1 | 2016 | 1 | 0.130 |
Why?
|
| Lymphocytosis | 1 | 2016 | 14 | 0.130 |
Why?
|
| Melanoma | 1 | 2023 | 834 | 0.130 |
Why?
|
| Skin Neoplasms | 1 | 2023 | 804 | 0.130 |
Why?
|
| Piperazines | 2 | 2014 | 238 | 0.120 |
Why?
|
| Papillomavirus Infections | 1 | 2018 | 288 | 0.110 |
Why?
|
| Aged, 80 and over | 5 | 2025 | 6521 | 0.100 |
Why?
|
| Aged | 7 | 2025 | 19691 | 0.080 |
Why?
|
| Middle Aged | 8 | 2025 | 26716 | 0.080 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2017 | 1028 | 0.080 |
Why?
|
| Papillomaviridae | 2 | 2018 | 137 | 0.070 |
Why?
|
| Adult | 7 | 2025 | 29471 | 0.070 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2016 | 68 | 0.060 |
Why?
|
| Treatment Outcome | 6 | 2018 | 12342 | 0.060 |
Why?
|
| Pleural Effusion | 2 | 2016 | 101 | 0.060 |
Why?
|
| Male | 9 | 2025 | 61283 | 0.060 |
Why?
|
| Female | 9 | 2025 | 66553 | 0.060 |
Why?
|
| Young Adult | 4 | 2023 | 8987 | 0.060 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2023 | 55 | 0.050 |
Why?
|
| Combined Modality Therapy | 2 | 2017 | 1247 | 0.050 |
Why?
|
| Coloring Agents | 1 | 2023 | 79 | 0.050 |
Why?
|
| Azacitidine | 1 | 2022 | 53 | 0.050 |
Why?
|
| Indocyanine Green | 1 | 2023 | 59 | 0.050 |
Why?
|
| Optical Imaging | 1 | 2023 | 66 | 0.050 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2022 | 76 | 0.050 |
Why?
|
| Humans | 11 | 2025 | 124793 | 0.050 |
Why?
|
| Follow-Up Studies | 3 | 2016 | 5153 | 0.050 |
Why?
|
| Cohort Studies | 2 | 2023 | 4783 | 0.050 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2016 | 720 | 0.040 |
Why?
|
| Retrospective Studies | 4 | 2023 | 16299 | 0.040 |
Why?
|
| Disease Progression | 1 | 2025 | 2052 | 0.040 |
Why?
|
| Treponema denticola | 1 | 2018 | 2 | 0.040 |
Why?
|
| Toll-Like Receptor 5 | 1 | 2018 | 8 | 0.040 |
Why?
|
| Toll-Like Receptor 7 | 1 | 2018 | 8 | 0.040 |
Why?
|
| Finland | 1 | 2017 | 42 | 0.040 |
Why?
|
| Neck Dissection | 1 | 2017 | 18 | 0.040 |
Why?
|
| Hospitals, University | 1 | 2017 | 97 | 0.030 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2017 | 143 | 0.030 |
Why?
|
| Prognosis | 2 | 2018 | 4607 | 0.030 |
Why?
|
| Chemoradiotherapy | 1 | 2017 | 104 | 0.030 |
Why?
|
| Pancytopenia | 1 | 2016 | 40 | 0.030 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2018 | 170 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2017 | 428 | 0.030 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2016 | 72 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2022 | 1237 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2017 | 611 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2018 | 1690 | 0.030 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 2014 | 41 | 0.030 |
Why?
|
| Time | 1 | 2014 | 94 | 0.030 |
Why?
|
| Killer Cells, Natural | 1 | 2016 | 324 | 0.030 |
Why?
|
| Cytogenetic Analysis | 1 | 2013 | 79 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2017 | 1495 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2017 | 1228 | 0.030 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2016 | 501 | 0.030 |
Why?
|
| Patient Safety | 1 | 2016 | 398 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2016 | 1108 | 0.020 |
Why?
|
| Adolescent | 2 | 2023 | 19329 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2018 | 1898 | 0.020 |
Why?
|
| Incidence | 1 | 2016 | 3144 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2017 | 3435 | 0.020 |
Why?
|
| Time Factors | 1 | 2013 | 6309 | 0.010 |
Why?
|
| Child | 1 | 2023 | 24453 | 0.010 |
Why?
|